![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IL3RA |
Gene summary for IL3RA |
![]() |
Gene information | Species | Human | Gene symbol | IL3RA | Gene ID | 3563 |
Gene name | interleukin 3 receptor subunit alpha | |
Gene Alias | CD123 | |
Cytomap | X | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | P26951 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3563 | IL3RA | HTA11_347_2000001011 | Human | Colorectum | AD | 7.16e-11 | 4.25e-01 | -0.1954 |
3563 | IL3RA | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.72e-03 | 3.66e-01 | -0.1207 |
3563 | IL3RA | HTA11_696_2000001011 | Human | Colorectum | AD | 2.65e-15 | 3.95e-01 | -0.1464 |
3563 | IL3RA | HTA11_866_2000001011 | Human | Colorectum | AD | 1.70e-07 | 3.05e-01 | -0.1001 |
3563 | IL3RA | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.85e-11 | 5.06e-01 | -0.059 |
3563 | IL3RA | HTA11_546_2000001011 | Human | Colorectum | AD | 1.95e-04 | 3.59e-01 | -0.0842 |
3563 | IL3RA | HTA11_866_3004761011 | Human | Colorectum | AD | 4.78e-02 | 1.74e-01 | 0.096 |
3563 | IL3RA | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.81e-03 | 3.28e-01 | 0.0338 |
3563 | IL3RA | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.72e-07 | 3.18e-01 | 0.0674 |
3563 | IL3RA | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.39e-02 | 6.79e-01 | 0.3487 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL3RA | SNV | Missense_Mutation | rs200321061 | c.502N>A | p.Asp168Asn | p.D168N | P26951 | protein_coding | tolerated(0.41) | benign(0.062) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD |
IL3RA | SNV | Missense_Mutation | c.1035C>G | p.Ile345Met | p.I345M | P26951 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
IL3RA | SNV | Missense_Mutation | c.133N>G | p.Arg45Gly | p.R45G | P26951 | protein_coding | tolerated(1) | benign(0) | TCGA-86-7714-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
IL3RA | SNV | Missense_Mutation | novel | c.650G>T | p.Cys217Phe | p.C217F | P26951 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-MP-A4T9-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | vinorelbine | PD |
IL3RA | SNV | Missense_Mutation | novel | c.453N>G | p.Cys151Trp | p.C151W | P26951 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-34-2608-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
IL3RA | SNV | Missense_Mutation | novel | c.415N>C | p.Tyr139His | p.Y139H | P26951 | protein_coding | tolerated(0.15) | possibly_damaging(0.796) | TCGA-34-8454-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
IL3RA | SNV | Missense_Mutation | novel | c.332N>T | p.Thr111Ile | p.T111I | P26951 | protein_coding | tolerated(0.05) | possibly_damaging(0.879) | TCGA-CR-5250-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
IL3RA | SNV | Missense_Mutation | rs764345006 | c.863N>T | p.Pro288Leu | p.P288L | P26951 | protein_coding | deleterious(0.01) | possibly_damaging(0.887) | TCGA-CV-5979-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IL3RA | SNV | Missense_Mutation | rs754562435 | c.589N>T | p.Asp197Tyr | p.D197Y | P26951 | protein_coding | deleterious(0) | possibly_damaging(0.826) | TCGA-CV-A45V-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IL3RA | SNV | Missense_Mutation | novel | c.821C>G | p.Ala274Gly | p.A274G | P26951 | protein_coding | tolerated(0.18) | possibly_damaging(0.487) | TCGA-CV-A45Z-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Flotetuzumab | FLOTETUZUMAB | ||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | MGD006 | FLOTETUZUMAB | ||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | 178101691 | ||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | IL-3 | 8910323 | ||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | 4SCAR19 and 4SCAR123 | |||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | JNJ-63709178 | |||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CSL-362-AML | |||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | EPO | EPOETIN ALFA | 8910323 | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CSL 360 | |||
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CAR-T cells targeting CD123 |
Page: 1 2 3 |